PMID- 29736587 OWN - NLM STAT- MEDLINE DCOM- 20190321 LR - 20221207 IS - 1432-0584 (Electronic) IS - 0939-5555 (Linking) VI - 97 IP - 9 DP - 2018 Sep TI - A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion. PG - 1663-1669 LID - 10.1007/s00277-018-3359-9 [doi] AB - Previous studies showed that, in chronic lymphocytic leukemia (CLL) patients with isolated 13q deletion (13q-), those carrying higher percentage of leukemic cells with 13q- had more aggressive diseases. However, the prognostic value of the percentage of leukemic cells with 13q- in Chinese CLL patients with isolated 13q- remained to be determined. Using interphase fluorescence in situ hybridization (FISH), we identified 82 patients (25.4%) with isolated 13q deletion from a cohort of 323 untreated CLL patients. Among patients with isolated 13q deletion, cases of 13q- cells >/= 80% (13q-H) had significantly shorter time to first treatment (TTT) than those of < 80% 13q- cells (13q-L) (median 11 vs. 92 months, p = 0.0016). A higher lymphocyte count (p = 0.0650) was associated with 13q-H, while other clinical, immunophenotypic, or molecular features did not differ between patients with 13q-H and 13q-L. Although 13q-H only showed marginal significance in multivariate analysis of TTT (hazards ratio 2.007; 95% confidence interval 0.975-4.129; p = 0.059), it helped refine the risk stratification based on Binet stage or immunoglobulin heavy chain variable gene (IGHV) status. In cases in Binet A or B stage, patients with 13q-H had a significantly shorter TTT (median TTT 18 months vs. undefined, p = 0.0101). And in IGHV mutated patients, 13q-H was also associated with reduced TTT (median TTT 13q-H. 18 months vs. 13q-L undefined, p = 0.0163). In conclusion, the prognosis of CLL patients with isolated 13q deletion was heterogeneous with 13q-H identifying patients with worse outcome. FAU - Miao, Yuqing AU - Miao Y AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. AD - Department of Hematology, The First People's Hospital of Yancheng, Yancheng, Jiangsu Province, China. FAU - Miao, Yi AU - Miao Y AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Shi, Ke AU - Shi K AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Sun, Qian AU - Sun Q AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Zhao, Si-Shu AU - Zhao SS AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Xia, Yi AU - Xia Y AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Qin, Shu-Chao AU - Qin SC AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Qiu, Hai-Rong AU - Qiu HR AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Yang, Hui AU - Yang H AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Xu, Hao AU - Xu H AD - Department of Hematology, The First People's Hospital of Yancheng, Yancheng, Jiangsu Province, China. FAU - Zhu, Hua-Yuan AU - Zhu HY AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Wu, Jia-Zhu AU - Wu JZ AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Wu, Wei AU - Wu W AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Cao, Lei AU - Cao L AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Wang, Li AU - Wang L AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Fan, Lei AU - Fan L AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. FAU - Xu, Wei AU - Xu W AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. xuwei10000@hotmail.com. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. xuwei10000@hotmail.com. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. xuwei10000@hotmail.com. FAU - Li, Jian-Yong AU - Li JY AD - Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China. lijianyonglm@medmail.com.cn. AD - Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. lijianyonglm@medmail.com.cn. AD - Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. lijianyonglm@medmail.com.cn. LA - eng GR - 30971296, 81170485, 81170488, 81370657, 81470328, 81500125, 81522001, 81570141/National Natural Science Foundation of China/ GR - 2014BAI09B12/National Key Clinical Specialty, the National Science & Technology Pillar Program/ GR - BL2014086/Jiangsu Provincial Special Program of Medical Science/ PT - Clinical Trial PT - Journal Article PT - Multicenter Study DEP - 20180507 PL - Germany TA - Ann Hematol JT - Annals of hematology JID - 9107334 RN - 13q deletion syndrome SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Asian People MH - China/epidemiology MH - *Chromosome Deletion MH - *Chromosome Disorders/genetics/mortality MH - Chromosomes, Human, Pair 13/genetics MH - Disease-Free Survival MH - Female MH - Humans MH - In Situ Hybridization, Fluorescence MH - *Leukemia, Lymphocytic, Chronic, B-Cell/genetics/mortality MH - Male MH - Middle Aged MH - Survival Rate OTO - NOTNLM OT - 13q deletion OT - Chronic lymphocytic leukemia OT - FISH OT - Prognosis EDAT- 2018/05/08 06:00 MHDA- 2019/03/22 06:00 CRDT- 2018/05/09 06:00 PHST- 2017/12/16 00:00 [received] PHST- 2018/04/28 00:00 [accepted] PHST- 2018/05/08 06:00 [pubmed] PHST- 2019/03/22 06:00 [medline] PHST- 2018/05/09 06:00 [entrez] AID - 10.1007/s00277-018-3359-9 [pii] AID - 10.1007/s00277-018-3359-9 [doi] PST - ppublish SO - Ann Hematol. 2018 Sep;97(9):1663-1669. doi: 10.1007/s00277-018-3359-9. Epub 2018 May 7.